PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: MERCOSUR (Argentina, Brazil, Paraguay, Uruguay)

PE Guidelines
MERCOSUR - GUÍA PARA ESTUDIOS DE EVALUACIÓN ECONÓMICA DE TECNOLOGÍAS SANITARIAS/ GUIDELINE FOR ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES

PE Guidelines Source:
Common Market of the Southern Cone (MERCOSUR): Argentina, Brazil, Paraguay, Uruguay.
http://www.mercosur.int

Additional Information:

Last Webpage Update: Monday, January 15, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the documentGUIDELINES FOR ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES (2015)  
Affiliation of authors 
Purpose of the documentTo establish the procedures and methods to be used by analysts and researchers to produce, conduct, describe, report, and assess economic evaluations of health technologies in the member states.  
Standard reporting format includedYes 
DisclosureYes 
Target audience of funding/ author's interestsResearchers who conduct EE and decision makers  
PerspectiveMust be defined and reported. For decisions related to public policies, the preferred perspective should be the one of the public health system. Society perspective should include, all the direct costs of the production of the service/procedure, the times lost by the patients and their relatives, and the costs related to the loss of productivity and premature death.  
IndicationNot specified.  
Target populationMust be clearly specified which population groups or subgroups will benefit from the inclusion of the new technology (target population). The population included in the EE should be specified and fully described (sociodemographic characteristics according to the nature, progression or severity of the disease and the existence of comorbidities and/or other aggravating factors). If data on effectiveness was obtained from multiple sources of different populations, the report must provide a detailed description of the method used to arrive at the definition of the target population and to estimate of the effectiveness.  
Subgroup analysisYes 
Choice of comparatorComparators must be relevant and cover all the usual alternatives to all proposed uses of the assessed technology.  
Time horizonMust be mention and justified. For chronic diseases and conditions with significant differences in survival, the time horizon should be life expectancy. If a long term analysis is impossible, a shorter analysis should be justified and made using feasible data.  
Assumptions requiredNot specified.  
Preferred analytical techniqueThere is no preference, the analytical technique should be justified and adequate to answer the research question.  
Costs to be includedShould be appropriate for the chosen perspective (direct health care costs, indirect costs, patient and family costs, productivity loss).  
Source of costsShould be described and justified.  
ModelingModeling methodology should be described and justified, it must be possible to incorporate all relevant parameters and disease stages. Model must be flexible and adaptable.  
Systematic review of evidencesNot specified.  
Preference for effectiveness over efficacyYes  
Preferred outcome measureEffectiveness  
Preferred method to derive utilityShould be described and justified.  
Equity issues statedYes. A detailed discussion should be included on the possible effects of the distribution of the health interventions or programs considered in different population groups, and other aspects related to equity in the allocation of resources.  
Discounting costsYes 
Discounting outcomesYes 
Sensitivity analysis-parameters and rangeShould be described and justified.  
Sensitivity analysis-methodsShould be described and justified.  
Presenting resultsReport has to be clear, transparent and detailed. The guideline describe the recommended format.  
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Yes 
Portability of results (Generalizability)Not specified.  
Financial impact analysisBIA must be provided  
Mandatory or recommended or voluntaryRecommended  

Acknowledgement: Ramiro Gilardino, MD, MSc, Director - Global Networks Latin America, ISPOR, Lawrenceville, NJ, USA and Lucila Rey Ares, MD MSc, Head of Medical Audit, Centro de Educación Médica e Investigación Clínica (CEMIC), Buenos Aires, Argentina contributed to the key feature form. Natalia Jorgensen, BEc, MSc, Associate Manager of Cost Assessment, Argentinean Health Superintendence, Buenos Aires, Argentina reviewed the guidelines for accuracy.

Country Selection Page | PE Guidelines Index Page